LabCorp COVID-19 tests free for 3 months to aid plasma donations


Leading testing company LabCorp is offering a “no charge” antibody COVID-19 testing program in the hope it will boost blood plasma donations.

A number of biopharmas, including the likes of Takeda, are hoping to use donated blood plasma from those who have recovered from COVID-19 and tap their antibodies as a potential therapy for the disease.

It hopes that by offering a test for free, this will boost uptake and deepen the plasma pool, offering potential new vehicles for treatments in the future.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

“Beginning today for the next three months, LabCorp will perform the high-affinity antibody test at no charge to patients, insurance companies or the government,” it said in a statement.

In the small print, that no-charge testing program will use only the Roche Elecsys Anti-SARS-CoV-2, authorized under an FDA emergency use authorization (EUA), but does not apply to other COVID-19 antibody tests, such as the IgG test.

Once tested, patients can get their results via the LabCorp Patient portal and through their doctor. The CDC and state public health agencies will also get their hands on the data “to further support COVID-19 surveillance and response efforts.”

“Many people have antibodies and are unaware that they could potentially use them to help save lives. LabCorp is offering antibody tests at no charge through a patient’s doctor to make it easier for more people to know if they should consider giving plasma,” said Adam Schechter, chairman and CEO of LabCorp.

“If you have antibodies and donate your plasma, you are helping the fight against the pandemic,” he added.


Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.